Scholars@Duke
Trudy G Oliver

Trudy G Oliver

Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
trudy.oliver@duke.edu
Campus Box 3813, Durham, NC 27708
308 Research Drive, LSRC C138B, Durham, NC 27708

Selected Publications

KSR2 promotes self-renewal and clonogenicity of small-cell lung carcinoma.

Journal Article Mol Cancer Res · March 10, 2025 Small-cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. Here, we show that Kinase Suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffo ... Full text Link to item Cite

Supplementary Data Figure S6 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>Differential expression of genes and gene signatures in RPM and RPMA allografts.</p> ... Full text Cite

Supplementary Data Figure S4 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>Sorting parameters for TdTom + tumor cells used for seeding secondary allograft tumors.</p> ... Full text Cite

Gels and unmerged images from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>PCR genotyping gels and unmerged images from immunofluorescence.</p> ... Full text Cite

Supplementary Data Figure S5 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>Genotypes of RPMA organoids and differences in metastatic burden.</p> ... Full text Cite

Supplementary Data Figure S2 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>IHC characterization of RPM tumors and histopathology assessment of allografts.</p> ... Full text Cite

Supplementary Data Figure S3 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>Castration does not alter growth or heterogeneity of RPM and RPMA allograft tumors</p> ... Full text Cite

Supplementary Data Figure S1 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · January 10, 2025 <p>Genotypes of prostate organoids and resulting allograft tumors.</p> ... Full text Cite

Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer.

Journal Article bioRxiv · November 15, 2024 Neuroendocrine and tuft cells are rare, chemosensory epithelial lineages defined by expression of ASCL1 and POU2F3 transcription factors, respectively1,2. Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like subsets ... Full text Link to item Cite

Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.

Chapter · November 4, 2024 Most patients with prostate adenocarcinoma develop resistance to therapies targeting the androgen receptor (AR). Consequently, a portion of these patients develop AR-independent neuroendocrine (NE) prostate cancer (NEPC), a rapidly progressing cancer with ... Full text Link to item Cite

Supplementary Data Figure S3 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>Castration does not alter growth or heterogeneity of RPM and RPMA allograft tumors</p> ... Full text Cite

Supplementary Data Figure S2 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>IHC characterization of RPM tumors and histopathology assessment of allografts.</p> ... Full text Cite

Gels and unmerged images from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>PCR genotyping gels and unmerged images from immunofluorescence.</p> ... Full text Cite

Supplementary Data Figure S6 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>Differential expression of genes and gene signatures in RPM and RPMA allografts.</p> ... Full text Cite

Data from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <div>Abstract<p>Most patients with prostate adenocarcinoma develop resistance to therapies targeting the androgen receptor (AR). Consequently, a portion of these patients develop AR-independent neuroendocrine (NE) prostate cancer (NEPC) ... Full text Cite

Supplementary Data Figure S1 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>Genotypes of prostate organoids and resulting allograft tumors.</p> ... Full text Cite

Supplementary Data Figure S5 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>Genotypes of RPMA organoids and differences in metastatic burden.</p> ... Full text Cite

Supplementary Data Figure S4 from Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1

Other · November 4, 2024 <p>Sorting parameters for TdTom + tumor cells used for seeding secondary allograft tumors.</p> ... Full text Cite

Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization.

Journal Article Neoplasia · February 2024 INTRODUCTION: Pleomorphic liposarcoma is a rare and aggressive subset of soft-tissue sarcomas with a high mortality burden. Local treatment largely consists of radiation therapy and wide surgical resection, but options for systemic therapy in the setting o ... Full text Link to item Cite

Epigenetic Regulators Open the Door to SCLC Plasticity.

Journal Article Cancer Res · November 1, 2023 Small-cell lung cancer (SCLC) is a neuroendocrine tumor type with limited treatment options and poor prognosis. SCLC comprises multiple molecular subtypes that are defined by the expression of the lineage-related transcription factors ASCL1, NEUROD1, POU2F ... Full text Link to item Cite

Lineage Plasticity in SCLC Generates Non-Neuroendocrine Cells Primed for Vasculogenic Mimicry.

Journal Article J Thorac Oncol · October 2023 INTRODUCTION: Vasculogenic mimicry (VM), the process of tumor cell transdifferentiation to endow endothelial-like characteristics supporting de novo vessel formation, is associated with poor prognosis in several tumor types, including SCLC. In genetically ... Full text Link to item Cite

Supplementary Figure from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Figure from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Data from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 <div>Abstract<p>Genomic studies support the classification of small cell lung cancer (SCLC) into subtypes based on the expression of lineage-defining transcription factors ASCL1 and NEUROD1, which together are expressed in ∼86% of SCLC. ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Table from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

Data from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 <div>Abstract<p>Genomic studies support the classification of small cell lung cancer (SCLC) into subtypes based on the expression of lineage-defining transcription factors ASCL1 and NEUROD1, which together are expressed in ∼86% of SCLC. ... Full text Cite

Supplementary Figure from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer

Other · March 31, 2023 Supplementary Figure from Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer ... Full text Cite

BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation.

Journal Article Mol Cancer Res · February 1, 2023 UNLABELLED: Small-cell lung cancer (SCLC) is a recalcitrant malignancy that urgently needs new therapies. Four master transcription factors (ASCL1, NEUROD1, POU2F3, and YAP1) have been identified in SCLC, and each defines the transcriptome landscape of one ... Full text Link to item Cite

Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer.

Journal Article Cell Syst · September 21, 2022 Small cell lung cancer (SCLC) tumors comprise heterogeneous mixtures of cell states, categorized into neuroendocrine (NE) and non-neuroendocrine (non-NE) transcriptional subtypes. NE to non-NE state transitions, fueled by plasticity, likely underlie adapta ... Full text Link to item Cite

Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer.

Journal Article Cancer Res · September 2, 2022 UNLABELLED: Genomic studies support the classification of small cell lung cancer (SCLC) into subtypes based on the expression of lineage-defining transcription factors ASCL1 and NEUROD1, which together are expressed in ∼86% of SCLC. ASCL1 and NEUROD1 activ ... Full text Link to item Cite

TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.

Journal Article Oncogene · June 2022 Studies have shown that Nrf2E79Q/+ is one of the most common mutations found in human tumors. To elucidate how this genetic change contributes to lung cancer, we compared lung tumor development in a genetically-engineered mouse model (GEMM) with dual Trp53 ... Full text Link to item Cite

Killing SCLC: insights into how to target a shapeshifting tumor.

Journal Article Genes Dev · March 1, 2022 Small cell lung cancer (SCLC) is a rapidly growing, highly metastatic, and relatively immune-cold lung cancer subtype. Historically viewed in the laboratory and clinic as a single disease, new discoveries suggest that SCLC comprises multiple molecular subs ... Full text Link to item Cite

Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.

Journal Article Cancer Discov · December 1, 2021 UNLABELLED: Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in S ... Full text Link to item Cite

Tumor heterogeneity.

Journal Article Cancer Cell · August 9, 2021 Tumor heterogeneity was traditionally considered in the genetic terms, but it has now been broadened into many more facets. These facets represent a challenge in our understanding of cancer etiology but also provide opportunity for us to understand prognos ... Full text Link to item Cite

ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer.

Journal Article Genes Dev · June 2021 ASCL1 is a neuroendocrine lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ∼25% of human SCLC are ASCL1-low and associated with low neuroendocrine fate and high MYC expressio ... Full text Link to item Cite

Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.

Journal Article J Clin Invest · January 4, 2021 MYC stimulates both metabolism and protein synthesis, but how cells coordinate these complementary programs is unknown. Previous work reported that, in a subset of small-cell lung cancer (SCLC) cell lines, MYC activates guanosine triphosphate (GTP) synthes ... Full text Link to item Cite

A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest.

Journal Article Cell Rep · August 4, 2020 Cellular responses to stimuli can evolve over time, resulting in distinct early and late phases in response to a single signal. DNA damage induces a complex response that is largely orchestrated by the transcription factor p53, whose dynamics influence whe ... Full text Open Access Link to item Cite

MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.

Journal Article Cancer Cell · July 13, 2020 Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based on expression of ASCL1, NEUROD1, POU2F3, or YAP1. Here, we use mouse and human model ... Full text Link to item Cite

Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells.

Journal Article Immunity · May 19, 2020 Neutrophil extracellular traps (NETs) can promote tumor growth and metastases, but whether NETs impact the tumor immune microenvironment remains underexplored. In this issue of Immunity, Teijeira et al. discover that NETs shield tumor cells from cytotoxic ... Full text Link to item Cite

New Approaches to SCLC Therapy: From the Laboratory to the Clinic.

Journal Article J Thorac Oncol · April 2020 The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunothe ... Full text Link to item Cite

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.

Journal Article Nat Cancer · April 2020 The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. We generated circulating tu ... Full text Link to item Cite

Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells.

Journal Article Mol Oncol · April 2020 Platinum-based compounds remain a well-established chemotherapy for cancer treatment despite their adverse effects which substantially restrict the therapeutic windows of the drugs. Both the cell type-specific toxicity and the clinical responsiveness of tu ... Full text Open Access Link to item Cite

Leveraging insights into cancer metabolism-a symposium report.

Book · February 2020 Tumor cells have devised unique metabolic strategies to garner enough nutrients to sustain continuous growth and cell division. Oncogenic mutations may alter metabolic pathways to unlock new sources of energy, and cells take the advantage of various scaven ... Full text Link to item Cite

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.

Journal Article Clin Cancer Res · August 15, 2019 PURPOSE: Small-cell lung cancer (SCLC) has been treated clinically as a homogeneous disease, but recent discoveries suggest that SCLC is heterogeneous. Whether metabolic differences exist among SCLC subtypes is largely unexplored. In this study, we aimed t ... Full text Link to item Cite

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.

Journal Article Nat Commun · August 2, 2019 MYC paralogs are frequently activated in small cell lung cancer (SCLC) but represent poor drug targets. Thus, a detailed mapping of MYC-paralog-specific vulnerabilities may help to develop effective therapies for SCLC patients. Using a unique cellular CRIS ... Full text Link to item Cite

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Journal Article Nat Rev Cancer · July 2019 An amendment to this paper has been published and can be accessed via a link at the top of the paper. ... Full text Link to item Cite

Partners in Crime: Neutrophil-CTC Collusion in Metastasis.

Journal Article Trends Immunol · July 2019 A recent study in Nature (Szczerba et al. 2019;566:553-557) reports that the association of neutrophils with circulating tumor cells (CTCs) in the blood of patients with breast cancer can promote CTC proliferation and metastasis. These findings reveal a ne ... Full text Link to item Cite

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Journal Article Nat Rev Cancer · May 2019 Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective therapies are urgently needed. Several lines of evidence, from SCLC primary human tumours, patient-derived xenografts, cancer cell lines and genetically engineered ... Full text Link to item Cite

The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment.

Journal Article Immunity · October 16, 2018 The major types of non-small-cell lung cancer (NSCLC)-squamous cell carcinoma and adenocarcinoma-have distinct immune microenvironments. We developed a genetic model of squamous NSCLC on the basis of overexpression of the transcription factor Sox2, which s ... Full text Link to item Cite

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.

Journal Article Nat Commun · September 17, 2018 Nearly all patients with small cell lung cancer (SCLC) eventually relapse with chemoresistant disease. The molecular mechanisms driving chemoresistance in SCLC remain un-characterized. Here, we describe whole-exome sequencing of paired SCLC tumor samples p ... Full text Link to item Cite

Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.

Journal Article Cell Metab · September 4, 2018 Small cell lung cancer (SCLC) is a rapidly lethal disease with few therapeutic options. We studied metabolic heterogeneity in SCLC to identify subtype-selective vulnerabilities. Metabolomics in SCLC cell lines identified two groups correlating with high or ... Full text Link to item Cite

Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.

Journal Article Transl Lung Cancer Res · February 2018 BACKGROUND: Small cell lung cancer (SCLC) is a deadly, high grade neuroendocrine (NE) tumor without recognized morphologic heterogeneity. However, over 30 years ago we described a SCLC subtype with "variant" morphology which did not express some NE markers ... Full text Link to item Cite

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Journal Article Oncotarget · September 26, 2017 Small cell lung cancer (SCLC) is a recalcitrant cancer for which no new treatments have been approved in over 30 years. While molecular subtyping now guides treatment selection for patients with non-small cell lung cancer and other cancers, SCLC is still t ... Full text Link to item Cite

Family matters: How MYC family oncogenes impact small cell lung cancer.

Journal Article Cell Cycle · August 18, 2017 Small cell lung cancer (SCLC) is one of the most deadly cancers and currently lacks effective targeted treatment options. Recent advances in the molecular characterization of SCLC has provided novel insight into the biology of this disease and raises hope ... Full text Link to item Cite

MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Journal Article Cancer Cell · February 13, 2017 Loss of the tumor suppressors RB1 and TP53 and MYC amplification are frequent oncogenic events in small cell lung cancer (SCLC). We show that Myc expression cooperates with Rb1 and Trp53 loss in the mouse lung to promote aggressive, highly metastatic tumor ... Full text Link to item Cite

Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo.

Journal Article Cell Death Differ · May 2015 Caspase-2 is an atypical caspase that regulates apoptosis, cell cycle arrest and genome maintenance, although the mechanisms are not well understood. Caspase-2 has also been implicated in chemotherapy response in lung cancer, but this function has not been ... Full text Link to item Cite

Squamous non-small cell lung cancer as a distinct clinical entity.

Journal Article Am J Clin Oncol · April 2015 Traditionally, the treatment of lung cancer has been based on histologic type [non-small cell lung cancer (NSCLC) or small cell lung cancer], performance status, and stage of disease. However, more recently, treatment decisions are being made based on mole ... Full text Link to item Cite

Mighty mouse breakthroughs: a Sox2-driven model for squamous cell lung cancer.

Journal Article Mol Cell Oncol · 2015 Squamous lung cancer is a subtype of non-small cell lung cancer with a poor overall prognosis. We have recently generated a mouse model of squamous lung carcinoma by overexpressing Sex-determining region Y-box 2 (Sox2) and deleting liver kinase B1 (Lkb1) u ... Full text Link to item Cite

Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer.

Journal Article Cell Rep · July 10, 2014 Squamous cell carcinoma (SCC) of the lung is the second most common subtype of lung cancer. With limited treatment options, the 5-year survival rate of SCC is only 15%. Although genomic alterations in SCC have been characterized, identifying the alteration ... Full text Link to item Cite

Bosom buddies: Close connections between breast and bladder cancer

Journal Article Science Translational Medicine · February 26, 2014 Full text Cite

RIG-ging biomarkers for therapeutic response

Journal Article Science Translational Medicine · January 15, 2014 Full text Cite

Waking a sleeping giant...on purpose?

Journal Article Science Translational Medicine · November 27, 2013 Full text Cite

An anti-depressing discovery for lung cancer treatment

Journal Article Science Translational Medicine · October 16, 2013 Full text Cite

Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction.

Journal Article Cancer Discov · August 2013 PTEN loss is considered a biomarker for activated phosphoinositide 3-kinase (PI3K)/AKT, a pathway frequently mutated in cancer, and was recently shown to confer resistance to dietary restriction. Here, we show that Pten loss is not sufficient to drive AKT ... Full text Link to item Cite

Cancer: An inferiority complex for chemo

Journal Article Science Translational Medicine · July 24, 2013 Full text Cite

A two hit wonder for melanoma treatment

Journal Article Science Translational Medicine · June 12, 2013 Full text Cite

Dangerous liaisons: When two wrongs just might make a right

Journal Article Science Translational Medicine · May 1, 2013 Full text Cite

Ovarian stem cells find their niche

Journal Article Science Translational Medicine · March 20, 2013 Full text Cite

Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma.

Journal Article Cancer Discov · August 2011 UNLABELLED: Lung adenocarcinoma is a leading cause of cancer death worldwide. We recently showed that genetic inhibition of the NF-κB pathway affects both the initiation and the maintenance of lung cancer, identifying this pathway as a promising therapeuti ... Full text Link to item Cite

Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop.

Journal Article Mol Cell · July 8, 2011 Caspase-2 is an evolutionarily conserved caspase, yet its biological function and cleavage targets are poorly understood. Caspase-2 is activated by the p53 target gene product PIDD (also known as LRDD) in a complex called the Caspase-2-PIDDosome. We show t ... Full text Link to item Cite

Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy.

Journal Article Proc Natl Acad Sci U S A · November 30, 2010 Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymeras ... Full text Link to item Cite

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer.

Journal Article Genes Dev · April 15, 2010 Chemotherapy resistance is a major obstacle in cancer treatment, yet the mechanisms of response to specific therapies have been largely unexplored in vivo. Employing genetic, genomic, and imaging approaches, we examined the dynamics of response to a mainst ... Full text Link to item Cite

Aurora-A kinase is essential for bipolar spindle formation and early development.

Journal Article Mol Cell Biol · February 2009 Aurora-A is a conserved kinase implicated in mitotic regulation and carcinogenesis. Aurora-A was previously implicated in mitotic entry and spindle assembly, although contradictory results prevented a clear understanding of the roles of Aurora-A in mammals ... Full text Link to item Cite

Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis.

Journal Article Cancer Res · January 1, 2009 Bub1 is a serine/threonine kinase originally described as a core component of the spindle assembly checkpoint (SAC) mechanism in yeast. Bub1 binding at kinetochores has been reported to be required for SAC function and localization of other SAC components. ... Full text Link to item Cite

Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells.

Journal Article Proc Natl Acad Sci U S A · February 20, 2007 The Sonic hedgehog (Shh) and FGF signaling pathways regulate growth and differentiation in many regions of the nervous system, but interactions between these pathways have not been studied extensively. Here, we examine the relationship between Shh and FGF ... Full text Link to item Cite

Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma.

Journal Article Development · May 2005 Medulloblastoma is the most common malignant brain tumor in children. It is thought to result from the transformation of granule cell precursors (GCPs) in the developing cerebellum, but little is known about the early stages of the disease. Here, we identi ... Full text Link to item Cite

Getting at the root and stem of brain tumors.

Journal Article Neuron · June 24, 2004 Brain tumors are among the most aggressive and intractable types of cancer. Recent studies indicate that brain tumor cells resemble neural stem cells in terms of phenotype, signaling, and behavior in vitro. In light of these similarities, it has been sugge ... Full text Link to item Cite

Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors.

Journal Article Proc Natl Acad Sci U S A · June 10, 2003 Cerebellar granule cells are the most abundant neurons in the brain, and granule cell precursors (GCPs) are a common target of transformation in the pediatric brain tumor medulloblastoma. Proliferation of GCPs is regulated by the secreted signaling molecul ... Full text Link to item Cite